Immunovant, Inc. Files 10-Q for Q3 2024
Ticker: IMVT · Form: 10-Q · Filed: Nov 7, 2024 · CIK: 1764013
Sentiment: neutral
Topics: 10-Q, biotech, financials
Related Tickers: IMVT
TL;DR
IMVT 10-Q filed: Q3 2024 financials out. Check for operational updates.
AI Summary
Immunovant, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial figures and operational details are presented in the filing.
Why It Matters
This filing provides investors with a detailed look at Immunovant's financial health and operational progress during the third quarter of 2024, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: medium — As a biotechnology company, Immunovant faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Immunovant, Inc. (company) — Filer of the 10-Q
- 2024-09-30 (date) — End of the reporting period
- 2024-11-07 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is for the period ended September 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on November 7, 2024.
What is the company's primary business sector?
Immunovant, Inc. is in the Biological Products sector, specifically SIC code 2836.
What was the former name of Immunovant, Inc.?
The former name of Immunovant, Inc. was Health Sciences Acquisitions Corp, with a date of name change on January 8, 2019.
What is the company's fiscal year end?
Immunovant, Inc.'s fiscal year ends on March 31.
Filing Stats: 4,569 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-11-07 06:49:49
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IMVT The Nasdaq Sto
Filing Documents
- imvt-20240930.htm (10-Q) — 1221KB
- exhibit101-2024930q2.htm (EX-10.1) — 69KB
- exhibit311-2024930q2.htm (EX-31.1) — 10KB
- exhibit312-2024930q2.htm (EX-31.2) — 10KB
- exhibit321-2024930q2.htm (EX-32.1) — 4KB
- exhibit322-2024930q2.htm (EX-32.2) — 4KB
- imvt-20240930_g1.jpg (GRAPHIC) — 143KB
- imvt-20240930_g2.jpg (GRAPHIC) — 152KB
- 0001764013-24-000184.txt ( ) — 5450KB
- imvt-20240930.xsd (EX-101.SCH) — 26KB
- imvt-20240930_cal.xml (EX-101.CAL) — 38KB
- imvt-20240930_def.xml (EX-101.DEF) — 149KB
- imvt-20240930_lab.xml (EX-101.LAB) — 440KB
- imvt-20240930_pre.xml (EX-101.PRE) — 301KB
- imvt-20240930_htm.xml (XML) — 359KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements (unaudited)
Item 1. Financial Statements (unaudited) 4 Condensed Consolidated Balance Sheets as of September 30, 2024 and March 31, 2024 4 Condensed Consolidated Statements of Operations for the Three and Six Months Ended September 30, 2024 and 2023 5 Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended September 30, 2024 and 2023 6 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended September 30, 2024 and 2023 7 Condensed Consolidated Statements of Cash Flows for the Six Months Ended September 30, 2024 and 2023 8 Notes to Condensed Consolidated Financial Statements 9
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 18
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 32
Controls and Procedures
Item 4. Controls and Procedures 32
OTHER INFORMATION
PART II. OTHER INFORMATION
Legal Proceedings
Item 1. Legal Proceedings 33
Risk Factors
Item 1A. Risk Factors 33
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 85
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 85
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 85
Other Information
Item 5. Other Information 85
Exhibits
Item 6. Exhibits 86
SIGNATURES
SIGNATURES 87 Where You Can Find More Information Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (www.immunovant.com), filings we make with the Securities and Exchange Commission, webcasts, press releases, and conference calls. We use these mediums, including our website, to communicate with our stockholders and the public about our company, our product candidates, and other matters. It is possible that the information that we make available may be deemed to be material information. We therefore encourage investors and others interested in our company to review the information that we make available on our website. The information contained on the website referenced in this Quarterly Report on Form 10-Q is not incorporated by reference into this filing, and the website address is provided only as an inactive textual reference. All trademarks, trade names, service marks, and copyrights appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. 1 Table of Contents SUMMARY RISK FACTORS You should consider carefully the risks described under "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q. References to "we," "us," and "our" in this section titled "Summary Risk Factors" refer to Immunovant, Inc. and its wholly owned subsidiaries. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following: Our business is currently dependent on the successful and timely development, regulatory approval and commercialization of our product candidates. Our product candidates, or anti-FcRn product candidates or products developed by others, may cause adverse events or undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical t
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements IMMUNOVANT, INC. Condensed Consolidated Balance Sheets (Unaudited, in thousands, except share and per share data) September 30, 2024 March 31, 2024 Assets Current assets: Cash and cash equivalents $ 472,941 $ 635,365 Accounts receivable 1,876 5,337 Prepaid expenses and other current assets 32,555 25,068 Total current assets 507,372 665,770 Operating lease right-of-use assets 45 133 Other assets 7,619 — Property and equipment, net 671 462 Total assets $ 515,707 $ 666,365 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 20,727 $ 7,155 Accrued expenses 45,879 41,315 Current portion of operating lease liabilities 47 138 Total current liabilities 66,653 48,608 Total liabilities 66,653 48,608 Commitments and contingencies (Note 9) Stockholders' equity: Series A preferred stock, par value $ 0.0001 per share, 10,000 shares authorized, issued and outstanding at September 30, 2024 and March 31, 2024 — — Preferred stock, par value $ 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2024 and March 31, 2024 — — Common stock, par value $ 0.0001 per share, 500,000,000 shares authorized, 146,565,049 shares issued and outstanding at September 30, 2024 and 500,000,000 shares authorized, 145,582,999 shares issued and outstanding at March 31, 2024 14 14 Additional paid-in capital 1,469,082 1,441,518 Accumulated other comprehensive income 1,910 1,908 Accumulated deficit ( 1,021,952 ) ( 825,683 ) Total stockholders' equity 449,054 617,757 Total liabilities and stockholders' equity $ 515,707 $ 666,365 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 Table of Contents IMMUNOVANT, INC. Condensed Consolidated Statements of Operations (Unaudited, in thousands, except share and per share data) Three Months Ended September 30, Six Months Ended September 30, 2024 2023 2024 2023